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Abstract
Lipid and lipoprotein subclasses are associated with metabolic and cardiovascular dis-
eases, yet the genetic contributions to variability in subclass traits are not fully understood.
We conducted single-variant and gene-based association tests between 15.1M variants
from genome-wide and exome array and imputed genotypes and 72 lipid and lipoprotein
traits in 8,372 Finns. After accounting for 885 variants at 157 previously identified lipid loci,
we identified five novel signals near established loci at HIF3A, ADAMTS3, PLTP, LCAT,
and LIPG. Four of the signals were identified with a low-frequency (0.005<minor allele fre-
quency [MAF]<0.05) or rare (MAF<0.005) variant, including Arg123His in LCAT. Gene-
based associations (P<10−10) support a role for coding variants in LIPC and LIPG with lipo-
protein subclass traits. 30 established lipid-associated loci had a stronger association for a
subclass trait than any conventional trait. These novel association signals provide further
insight into the molecular basis of dyslipidemia and the etiology of metabolic disorders.
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Author summary
Lipid and lipoproteins are heritable traits that differ in content and size and are correlated
with coronary heart disease and mortality. To identify genetic variants associated with dif-
ferent subclasses of lipoproteins, we conducted a genome-wide association study of 8,372
Finnish men. We curated a dataset of all genetic variants known to be associated with
lipid or lipoprotein subclasses and used these data to conduct rigorous analyses to identify
new associations in the same gene region or new ones. We identified five new signals at
established lipid-associated loci revealing possible complex regulatory mechanisms under-
lying the signals. Using the contribution of rare coding variants predicted to be protein
truncating or missense, we uncovered novel associations for a set of variants at LIPC and
LIPG with HDL subclasses. Investigating the genetic association of lipoprotein subclass
traits may help lead to a better understanding of the etiology of cardio-metabolic diseases,
and provide novel therapeutic targets.
Introduction
Genome-wide association studies (GWAS) have identified hundreds of common (MAF>
0.05) variants associated with conventional lipid and lipoprotein traits: high-density lipo-
protein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol
(TC), and triglycerides (TG)[1–4]. While some low-frequency (0.005<MAF0.05) and
rare variants (MAF0.005) have been associated with lipid and lipoprotein traits, additional
loci remain to be identified[2,5,6]. High-throughput proton nuclear magnetic resonance
(NMR)-based measurements of lipid and lipoprotein subclasses provide a more compre-
hensive view of particle size and composition than conventional blood lipid profile mea-
surements[7], and these expanded sets of traits have been associated with metabolic and
cardiovascular diseases[8–10]. For example, HDL subclasses are differentially associated
with incidence of coronary heart disease, and VLDL particle size is negatively associated
with mortality[11,12].
Previous association studies for lipid traits have identified several genomic regions of<1
Mb that contain more than one association signal for which the lead variants are not in strong
linkage disequilibrium (LD) (r2<0.8)[2,3,13]. Fine-mapping with higher density variants and
conditional analyses can determine which signals are distinct (remain significant after condi-
tional analysis) and which are independent, which we define here as r2<0.01. For example,
Teslovich et al. used conditional analysis at 95 lipid loci to identify 26 loci that harbor at least
two distinct association signals[3]. Association signals at the same locus can be population-
specific or shared across populations, with potentially different effect sizes and/or lead variants
[13]. Multiple association signals at a locus may indicate allelic heterogeneity in gene function
or regulation or that more than one gene at the locus affects the trait[14]. Furthermore, identi-
fying and accounting for additional independent association signals increases the variance in
traits that can be explained by genetic loci[15,16].
In this study, we performed genome-wide single-variant and gene-based association analy-
ses of 68 NMR lipid and lipoprotein subclass traits and four conventional traits (TC, TG,
HDL-C, and LDL-C) in 8,372 non-diabetic Finnish men from the METabolic Syndrome In
Men (METSIM) study[17]. To identify novel associations, we performed analyses with and
without conditioning on lipid-associated variants at loci previously described in array- and
sequence-based GWAs. We identified the most strongly associated lipid and lipoprotein sub-
class traits at established loci for conventional lipid and lipoprotein traits. Since several
GWAS of 72 lipid and lipoprotein traits in Finns
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GWAS of 72 lipid and lipoprotein traits in Finns
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subclasses are associated with cardiovascular and metabolic diseases, identifying the variants
that influence these traits is the first step to develop novel clinical treatments. These expanded
association results have the potential to lead to advances in determining the etiological role of
the variants and genes in cardiovascular and metabolic disease.
Results
Genome-wide association study
To identify genetic variants associated with the 72 lipid and lipoprotein traits, we analyzed
15.1M genotyped and imputed variants in 8,372 non-diabetic Finnish men (S1 Table, S1 Fig).
Each trait was adjusted for age, age2, lipid-lowering medication use, and smoking status.
Inverse normalized trait residuals were tested for association with each variant assuming
additive allelic effects using a linear mixed model to account for relatedness among study par-
ticipants[18]. Many of the traits are highly correlated with each other, with 104 trait-pair com-
parisons having a pairwise Pearson correlation greater than 0.98 (S2 Fig). We used a genome-
wide significance threshold of P5×10−8, consistent with previous association studies of this
scale and high trait correlation[19]. We note where associations meet a conservative experi-
ment-wide Bonferonni-corrected P-value (P4.6×10−11). We identified 32,524 variant-trait
associations (Pdiscovery<5×10−8) for the 72 lipid and lipoprotein traits (S3 Fig). 30,348 (93%) of
the 32,524 associations were for one of the 68 subclass traits and 2,176 (7%) for one of the four
conventional lipid traits (TC, TG, HDL-C, LDL-C). More than half the associations were with
the VLDL- (38%) or HDL-subclass (29%) traits. 3,784 unique variants comprise the total 32,524
trait-variant associations (S2 Table). 73% (2,780) of the 3,784 variants had a greater association
with one of the 68 subclass traits, and 27% (1,004) were more highly associated with at least one
of the four conventional traits (S2 Table). These variants cluster into 42 loci that were associated
with at least one of the 72 traits (S1 Table). For example, at the well-characterized APOA5 locus
on chromosome 11, rs964184 was significantly associated (Pdiscovery<5×10−8) with 43 of the 72
lipid and lipoprotein traits. At CETP, rs12446515 was significantly associated with 34 of the 72
traits. For such loci, the high correlation between the traits obscures identification of a causal
trait underlying the signal.
Conditional analyses to identify novel loci and signals
To identify novel associations not reported previously for any conventional or subclass lipid or
lipoprotein trait, we identified and curated a list of previously known associated variants to use
in genome-wide conditional analyses (Methods). We identified 1,714 variants (S3 Table) that
we clustered based on stringent LD (r2>0.95) into 885 representative variants (S4 Table). After
genome-wide conditional analysis using these 885 variants, we defined novel association sig-
nals using a significance threshold of Pconditional<5×10−8 (S5 Table). Consistent with highly
correlated traits, we observed that most of the associated variants were associated with multiple
correlated traits. We considered variants located within 1 Mb of an established lipid or lipo-
protein signal to be an additional signal in the region, and we define a locus as the region 1 Mb
up- and downstream of a signal. We considered additional signals independent if the signal
was not in LD (r2<0.01) with known lipid/lipoprotein signals, and remained significant
(Psingle<5×10−8) after single-variant conditional analyses. Associated variants with MAF<0.01
were validated by direct genotyping or sequencing (see Methods). Using this genome-wide
conditional approach, we identified five novel signals near established lipid and lipoprotein
loci (Table 1).
GWAS of 72 lipid and lipoprotein traits in Finns
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One novel common variant signal at HIF3A
Common variant rs73059724 (MAF = 0.09), associated with decreased (β = –0.14) concentra-
tions of phospholipids in small VLDL, is located 3.5 kb upstream of HIF3A (hypoxia inducible
factor 3, alpha subunit) and 1.4 Mb from APOE (S4A and S5A Figs). Additionally, this signal is
associated with decreased VLDL subclass traits (S6 Fig). This signal achieved significance after
conditioning on known lipid GWAS variants (Pdiscovery = 3.8×10−7, Pconditional = 1.4×10−8)
(Table 1, S6 Table). When adjusted for total triglycerides, the strength of the association of
rs73059724 with phospholipids in small VLDL was reduced (P = 3.6×10−2, S7 Table). This sig-
nal is located in a gene-dense region on chromosome 19 that includes 10 previously reported
lipoprotein-associated variants within 1 Mb of the index variant (S6 Table)[20]; none of these
variants exhibited LD (r2>0.02) with rs73059724. Further analysis of the APOE locus with
additional samples may be necessary to elucidate the haplotype relationships between these
signals. Twenty-nine proxy variants in LD (r2>0.7) with rs73059724 span a 25-kb region
including the promoter and intron 1 of HIF3A, and five of these variants overlap5 liver and
adipose regulatory element (histone marks of transcriptional regulation and open chromatin)
datasets (S8 Table). Hyper-methylation at HIF3A is associated with increased adiposity and
BMI in Asian infants and children[21,22]. HIF3A is a known negative regulator of HIF1A
(hypoxia inducible factor 1, alpha subunit)[23], which has been shown to regulate the cellular
uptake of cholesterol esters and VLDL by creating hypoxic conditions[24]. One or more of the
associated variants may affect HIF3A transcription or other genes in the region, leading to
fewer phospholipids in small VLDL particles.
Two novel low-frequency variant signals at ALB and SYS1
We identified two new signals with low-frequency variants located near ALB and SYS1
(Table 1, S4B and S5B Figs). At the ALB locus, the low-frequency allele of rs187918276
(MAF = 0.017) located in intron 1 of ANKRD17was associated with increased (β = 0.60) con-
centration of small LDL particles (Pdiscovery = 6.3×10−22, Pconditional = 3.2×10−11) and 26 addi-
tional traits, including increased TC, LDL-C, esterified cholesterol, free cholesterol, and IDL/
LDL/VLDL subclasses (S6 Fig). When adjusted for total cholesterol, the strength of the associa-
tion of rs187918276 with small LDL particles was reduced (P = 9.1×10−7, S7 Table). Variants
in LD (r2>0.7, METSIM) with this variant span >1.2 Mb (S5B Fig, S8 Table), consistent with
long haplotypes previously described in Finns[25]. The 885 variants used for the conditional
analysis included established TC-associated signals at rs60873279 and rs182616603, located
337 kb and 1 Mb away; these variants exhibited low (r2<0.01) and moderate (r2 = 0.39) pair-
wise LD with rs187918276 (S6 Table). When conditioned on rs182616603, the association with
rs187918276 was reduced but still highly significant (Psingle = 5×10−15), suggesting the signals
are distinct. An additional variant at this locus, rs115136538, was reported previously to be
associated with albumin levels[5]. rs115136538 is located 710 kb away from and is not in LD
with rs187918276 (r2<0.01 in METSIM), and the association of rs187918276 with small LDL
particles was essentially unchanged when conditioned on rs115136538 (S6 Table). Taken
together, the ALB region contains three distinct signals for lipid traits (rs60873279, rs1826
16603, and now rs187918276).
ALB encodes albumin, which is responsible for shuttling cholesterol in the blood to the
lipoprotein particle acceptors; deletion of Alb in mice led to a hyperlipidemic condition
[26,27]. One of the 12 variants in LD (r2>0.7) with rs187918276, chr4:74265673, is located
4.3 kb upstream of the ALB transcription start site (TSS), and is the only variant that over-
lapped any epigenomic marks of transcriptional regulation from the adipose, blood, and liver
datasets (S8 Table). This variant may mediate a regulatory effect on ALB to increase the plasma
GWAS of 72 lipid and lipoprotein traits in Finns
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concentration of small LDL particles, or another of the candidate variants spanning 1.2 Mb
may act on this or another nearby gene.
In an intergenic region downstream of PIGT, we identified the low-frequency allele of lead
variant rs184392658 (MAF = 0.008) associated with the increased (β = 0.45) concentration of
large HDL particles (Pdiscovery = 2.3×10−7, Pconditional = 2.5×10−9, Table 1, S4C Fig and S5C Fig).
When adjusted for HDL-C, the association of rs184392658 with large HDL particles was
reduced (P = 4.1×10−5, S7 Table). Two previously established lipid-associated variants are
located within 1 Mb of rs184392658: rs1800961 near HNF4A and rs6065904 near PLTP.
rs184392658 was not in LD (r2<0.015) with either of these established variants, and condition-
ing on the individual known variants did not substantially change the association signal (all
Psingle<3.7×10−6, S6 Table). Thus, rs184392658 represents a new distinct signal in this region.
Of six variants in high LD (r2>0.7) with lead variant rs184392658, only rs149985455 overlaps
multiple epigenomic marks of transcription regulation from liver, blood, and adipose tissue
datasets (S8 Table). This variant is located 2.2 kb upstream from SYS1 (Sys1 Golgi trafficking
protein), which may have a role in lipid metabolism through an interaction with GTPases[28].
SYS1 targets ARFRP1 (ADP-ribosylation factor-related protein 1) and forms a complex in the
Golgi membrane[29]; deletion of Arfrp1 in mouse adipocytes led to lipodystrophy caused by
failure in lipid droplet formation[30]. rs149985455 may mediate a regulatory effect on SYS1 to
increase the plasma concentration of large HDL particles, or another of the candidate variants
spanning >500 kb may act on this or another nearby gene.
Two novel rare variant signals at LCAT and LIPG
We identified additional novel independent signals with rare variants near LCAT and LIPG
(Table 1). The rare allele (MAF = 0.005) of the missense variant rs199717050 (Arg123His) in
exon 3 of LCAT (lecithin-cholesterol acyltransferase) was associated with decreased (β = –0.72)
HDL-C levels (Pdiscovery = 5.9×10−10, Pconditional = 2.5×10−12, Table 1, S4D Fig and S5D Fig). This
signal was not significantly associated with any of the HDL subclass traits or other traits from
this study (S6 Fig). The association of rs199717050 with HDL-C was nominally reduced
(P = 2.9×10−8) when adjusted for total cholesterol (S7 Table). Six variants at this locus, within 1
Mb of rs199717050, were reported previously to be associated with HDL-C[2,4] (S6 Table).
However, these six variants all show low pairwise LD with rs199717050 (r2<0.01), and single-
variant conditional analyses using any one of the six variants did not substantially change the
association of rs199717050 with HDL-C (Psingle1.9×10−9, S6 Table). rs199717050 may be
nearly specific to Finns; the Exome Aggregation Consortium (ExAC) database shows a total
allele count of 16: fifteen in Finns and one in a non-European population. LCAT is responsible
for cholesterol esterification for eventual transfer into the lipoprotein core, and facilitates the
transport of cholesterol into the liver[31]. rs199717050 is predicted to be deleterious (SIFT,
0.02) or possibly damaging (PolyPhen, 0.55)[32], consistent with a plausible functional effect on
LCAT to decrease levels of HDL-C.
Another novel signal was located at the well-established HDL-C-associated LIPG locus (Fig
1)[33]. The rare allele (MAF = 0.004) of lead variant rs538509310 is located 3.6 kb upstream
from ACAA2, and was most strongly associated with increased (β = 0.72) levels of phospholip-
ids in medium-size HDL (Pdiscovery = 1.7×10−9, Pconditional = 3.2×10−10, Table 1, Fig 1A and 1B).
This signal was also significantly associated with increased levels of four other HDL subclass
traits and apolipoprotein A-I (S6 Fig). When adjusted for HDL-C, the association of rs53
8509310 with phospholipids in medium-size HDL was reduced (P = 4.5×10−5) (S7 Table).
rs538509310 is in near complete LD (r2 = 0.98) with rs201922257, which encodes a missense
substitution (Ala172Val) in exon 4 of LIPG. At least four previously described HDL-C variant
GWAS of 72 lipid and lipoprotein traits in Finns
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Fig 1. Novel independent signal at LIPG. Association with phospholipids in medium HDL at the LIPG locus. The
colors and shapes distinguish the association signals and are based on the LD (r2) in METSIM samples between each
GWAS of 72 lipid and lipoprotein traits in Finns
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association signals are located within 1 Mb of this variant, including rs74558535 (P = 2×10−10),
rs10438978 (P = 7.7×10−36), rs77960347 (P = 3.6×10−11), and rs2156552 (P = 2×10−12). The
new signal is not in LD (r2<0.043) with the previously described variants and remained signifi-
cant after single-variant conditional analyses (S6 Table, Fig 1C). LIPG encodes endothelial
lipase (EL), which catalyzes HDL phospholipids and aids in the sequestration of HDL from cir-
culation, and is expressed in several tissues and organs including the liver[34–36]. The associa-
tion with phospholipids in medium-size HDL is consistent with the known phospholipase of
EL[37]. Several variants in LIPG have been shown to decrease endothelial lipase levels and
increase HDL-C[38]. Based on the direction of effect in these previous studies, missense vari-
ant (A172V) may decrease function of LIPG, leading to increased phospholipids in medium-
size HDL and other HDL subclasses.
Gene-based tests of association
To test the association between lipid and lipoprotein subclasses and sets of coding variants
within a gene, we performed gene-based tests of association using SKAT-O with four variant
masks (Methods) based on the predicted function of the coding variants. Sets of variants in
LIPC (Pgene = 7.1×10−11) and LIPG (Pgene = 3.8×10−17) were associated with lipid and lipopro-
tein subclasses using the gene-based method; these results remained significant after adjusting
for nearby noncoding signals (LIPC P<1.3×10−10 and LIPG P<1.2×10−17) (Fig 2, S9 Table).
At LIPC, the set of five rare missense variants, R138C, A145T, R208H, R281Q, and R329H,
showed the strongest association using the protein truncating variant (PTV)+missense mask
with triglycerides in very large HDL (Fig 2A, Pgene = 7.1×10−11). Of the five single-variant tests
of association with triglycerides in very large HDL, A145T was individually the most significant
(Pdiscovery = 5.3×10−8). Four of the variants (R138C, A145T, R208H, and R281Q) showed higher
trait levels (β = 0.72 to 1.8) and were predicted to be deleterious by Variant Effect Predictor
(VEP), while R329H, observed in one individual, showed a modestly lower trait level (β = –
0.24) and was predicted to be benign[32]. While rare, A145T had 1.7-fold higher allele fre-
quency in Finns (0.003%) than other populations[39]. Three of the variants, A145T, R138C,
and R208H, were associated with increased HDL-C in a previous gene-based association study,
consistent with our results[40]. Among the other variants, the relatively high trait values for
R281Q suggest that it may also increase HDL-C. Based on previous data that decreased LIPC
expression can result in increased large HDL levels[41], the rare alleles may lead to reduced
LIPC function. Consistent with the gene-based test, deficiency in hepatic lipase activity resulted
in increased concentration of triglycerides in plasma HDL[42].
At LIPG, the PTV+missense mask showed five variants with the strongest association with
phospholipids in medium-size HDL (Fig 2B, Pgene = 3.8×10−17). Of the five single-variant tests, a
rare missense (A172V) variant rs201922257 was the only one significantly associated (Pdiscovery =
8.6×10−9) with the subclass trait, and in three of four transcripts the amino acid substitution is
predicted by VEP to be ‘deleterious’ and ‘probably damaging’ in most of the transcripts (Fig 2B).
This variant is in LD (r2 = 0.98) with the non-coding index variant rs538509310 for phospholipids
variant and a reference variant, rs538509310 or rs1943973, represented in red and blue, respectively. X-axis, genomic
(GRCh37/hg19) position in Mb. Left y-axis, p- value of variant-trait association in–log10. Right y-axis, local estimates of
genomic recombination rate in cM/Mb, represented by blue lines. (A) Unconditional association with phospholipids in
medium HDL. Black squares indicate the five coding variants (rs200435657, rs201922257, rs142545730, rs138438163,
and rs77960347) used in the LIPG gene-based association tests. (B) Association with phospholipids in medium HDL
after genome-wide conditional analysis of known lipid-associated variants (n = 885). (C) Association with phospholipids
in medium HDL after conditioning on rs538509310. The association plots for four additional signals at HIF3A, ALB,
SYS1, and LCAT are provided in S4 Fig and S5 Fig.
https://doi.org/10.1371/journal.pgen.1007079.g001
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in medium HDL (Table 1, Fig 1A). The other associated variants may also affect LIPG function
despite less-significant P-values. A splice variant rs200435657 (MAF = 0.0035, Pdiscovery =
4.0×10−6) is located at the 3’ end of intron 1; this variant has only been observed once (1/
121,029; 0.0008%) in non-Finnish ExAC samples. Based on position, this splice variant is pre-
dicted to cause skipping of exon 2, which would lead to four aberrantly coded amino acids and
a stop codon in exon 3. The remaining missense variants are predicted by VEP to be deleterious
except for E391K. N396S and E391K have been reported previously to be associated with
increased HDL-C levels[43–45]. However, our data suggest that all five variants increase phos-
pholipids in medium HDL (β = 0.01 to 0.75) (Fig 2B). Together, the gene-based tests suggest
that additional rare variants may influence LIPG function and HDL-C subclass levels.
Lipid and lipoprotein associations at known lipid and coronary artery
disease loci
We next asked whether any of 157 previously known loci associated with one or more of the
four conventional lipid and lipoprotein traits exhibited stronger evidence of association with
Fig 2. Gene-based tests of association with HDL subclass traits for LIPC and LIPG. The distribution of the inverse normalized residuals of the trait
values for all individuals (histogram) compared to individuals carrying variants included in the gene-based tests of association (triangles) (A) at LIPC with
triglycerides in very large HDL and (B) at LIPG with phospholipids in medium HDL. The histograms indicate counts of individuals per trait bin in the
METSIM study, and the dashed gray line below the histograms indicates the mean trait level. The rows of black and red triangles represent individuals that
are heterozygous and homozygous, respectively for each variant indicated, and the solid black lines indicate the mean trait level for variant carriers.
Pdiscovery, p-value for the individual variant-trait association; Pgene, p-value for the gene-based test of association; Annotation, functional annotation of the
variants; Splice accept., splice acceptor variant. Figure created with VARV (https://github.com/shramdas/varv).
https://doi.org/10.1371/journal.pgen.1007079.g002
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one of the lipid or lipoprotein subclass traits. Among the 157 loci associated (P<5×10−8) here
with at least one subclass trait, 30 showed stronger association with a subclass trait than any
conventional trait (Table 2, S7 Fig). For example, at PLTP (phospholipid transfer protein),
rs4812975 was much more strongly associated with HDL diameter (Psubclass = 1.4×10−15) than
with HDL-C (Pconventional = 2.6×10−3), consistent with PLTP mediating the net transfer of phos-
pholipids between lipoproteins and uptake of phospholipids into the HDL-C core[46]. In addi-
tion, at ANGPTL3 (angiopoietin-like 3), ANGPTL4 (angiopoietin-like 4), and LPL (lipoprotein
lipase), the variants were all more strongly associated with VLDL subclass traits than with the
conventional traits (Table 2), consistent with studies showing that mouse Angptl3 knockout and
Angptl4 overexpression may act via Lpl to decrease or increase VLDL, respectively[47,48].
At less well-characterized and gene-dense loci, lipid and lipoprotein subclass associations
may help suggest target genes or biological roles. At the gene-dense MTCH2-NUP160 locus,
rs4752801 was >3 log units more strongly associated with decreased free cholesterol in large
HDL levels (Psubclass = 1.4×10−9) than any conventional trait (HDL-C, Pconventional = 8.2×10−6,
Table 2). The pattern of association of rs4752801 with all 72 subclass traits (S7 Fig) is similar to
the pattern of association and direction of effect for at least two other signals, rs737337 at
ANGPTL8 and rs1129555 at GPAM. ANGPTL8 and GPAM are both regulated directly or indi-
rectly by LXR, encoded by NR1H3,[49,50] which is a positional candidate gene at this locus
[49,50]. Thus, the global pattern of association supports a contribution of NR1H3 at the
MTCH2-NUP160 locus and suggests that the lipid and lipoprotein subclass traits can be a use-
ful tool to help determine which genes underlie association signals.
We performed a similar analysis of lipoprotein associations at coronary artery disease
(CAD) loci (S10 Table). Variants at the APOA5/APOA1 locus were 5.2 log units more strongly
associated with triglycerides in small VLDL than total triglycerides, and APOE/APOC1was 2.3
log units more strongly associated with ratio of apoA-I/apoB than any conventional trait.
APOA5 has been shown to affect VLDL concentrations and TG-rich particle metabolism, and
the stronger association with the subclass trait is consistent with the known functions of these
genes[51].
Discussion
In this study we conducted GWAS for 72 lipid and lipoprotein subclass traits in 8,372 Finn-
ish men participating the METSIM study, and focused on identifying association signals
that had not been identified previously with any lipid or lipoprotein trait. From the litera-
ture of existing lipid and lipoprotein association studies, we identified 1,714 cholesterol,
TG, lipid, and lipoprotein-associated variants. We trimmed this list based on LD (r2>0.95)
to 885 variants to account for multiple known signals in a genome-wide conditional analy-
sis. With this approach, we identified five novel signals at established lipid loci. We con-
firmed that signals were independent by reciprocal conditional analyses.
This analysis focused on NMR measurements of 72 lipid and lipoprotein subclasses, includ-
ing four conventionally measured lipid traits: TC, TG, HDL-C, and LDL-C. 892 of the associa-
tion signals were located at or near loci previously associated with one or more of the four
conventional traits. Lipid and lipoprotein subclass traits have been linked to metabolic and
cardiovascular diseases, which underline their clinical importance[8–10]. We identified vari-
ants at 30 loci that showed a more significant association with a subclass trait than one of the
conventional lipid traits, consistent with previous observations[52].
The identification of multiple independent association signals at established GWAS loci
can provide supporting evidence to identify target genes, as with monogenic disorders. Loci
that harbor more than one association signal that affect transcriptional regulation of the same
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gene, or more than one coding variant that affect the same gene’s function, provide stronger
evidence for a gene’s role in determining trait variability. Multiple signals can be critical to
understanding the relationship between genetic variants and gene function, quantitative traits,
and disease[53]. Multiple association signals at established loci can also be used to detect
molecular interactions between coding and regulatory variants on protein levels[54]. In addi-
tion, multiple signals at the same locus may suggest that more than one nearby gene affects
trait variation, and the association signals may represent different routes of transcriptional reg-
ulation. Further study of the multiple association signals at a locus may more precisely define
the functional genetic mechanisms.
Table 2. Comparison of METSIM association data between conventional lipid traits and subclass traits at established loci.
Variant Chr:Position Locus Standard
Trait*
Pconventional Subclass Trait** Psubclass Log
Difference§
rs261291 15:58680178 LIPC HDL 1.2×10−17 Triglycerides in very large HDL 2.0×10−85 67.8
rs1065853 19:45413233 APOE LDL 5.1×10−50 Free cholesterol in large LDL 1.2×10−62 12.6
rs4812975 20:44545460 PLTP HDL 2.6×10−3 Mean HDL diameter 1.4×10−15 12.3
rs174554 11:61579463 FADS1-2-3 TG 1.7×10−4 Conc. of very large HDL particles 1.6×10−16 12.0
rs2156552 18:47181668 LIPG TC 5.7×10−3 Phospholipids in medium HDL 2.9×10−9 6.3
rs10864726 1:230296153 GALNT2 HDL 4.9×10−7 Cholesterol esters in medium HDL 2.1×10−12 5.4
rs964184 11:116648917 APOA1-C3-A4-A5 TG 1.0×10−30 Triglycerides in small VLDL 1.4×10−35 4.8
rs4752801 11:47907641 MTCH2-NUP160 HDL 8.2×10−6 Free cholesterol in large HDL 1.4×10−9 3.8
rs55714927 17:7080316 DLG4 TG 1.2×10−5 Free cholesterol 3.9×10−9 3.5
rs12130333 1:63191777 ANGPTL3 TC 2.9×10−4 Conc. of very small VLDL particles 1.0×10−7 3.5
rs193042029 17:4667984 TM4SF5 TG 1.2×10−5 Free cholesterol 3.9×10−9 3.5
rs3890182 9:107647655 ABCA1 HDL 1.2×10−4 Mean LDL diameter 4.6×10−8 3.4
rs3177928 6:32412435 HLA HDL 1.2×10−4 Triglycerides in IDL 4.6×10−8 3.4
rs2602836 4:100014805 ADH5 HDL 1.5×10−2 Total Cholesterol in very large HDL 7.3×10−6 3.3
rs58542926 19:19379549 TM6SF2 TG 1.4×10−8 Apolipoprotein B 9.1×10−12 3.2
rs141150988 19:38832410 KCNK6 TG 1.2×10−2 Triglycerides in CM and largest VLDL 1.6×10−5 2.9
rs115849089 8:19912370 LPL TG 5.8×10−13 Triglycerides in small VLDL 3.6×10−15 2.2
rs116843064 19:8429323 ANGPTL4 TG 1.1×10−7 Phospholipids in large HDL 8.2×10−10 2.1
rs2972146 2:227100698 IRS1 HDL 2.5×10−5 Mean HDL diameter 2.0×10−7 2.1
rs182616603 4:75084732 MTHFD2L TC 4.4×10−7 Conc. of small LDL particles 6.0×10−9 1.9
rs1129555 10:113910721 GPAM TG 3.0×10−4 Mean HDL diameter 3.4×10−6 1.9
rs2287623 2:169830155 ABCB11 TC 2.4×10−3 Free cholesterol 3.4×10−5 1.8
rs13392272 2:21217490 APOB LDL 3.0×10−8 Free cholesterol 5.7×10−10 1.7
rs1501908 5:156398169 TIMD4 TC 1.9×10−3 Triglycerides in IDL 4.7×10−5 1.6
rs737337 19:11347493 ANGPTL8 HDL 4.7×10−4 Phospholipids in large HDL 1.1×10−5 1.6
rs643531 9:15296034 TTC39B HDL 8.3×10−6 Free cholesterol in very large HDL 3.1×10−7 1.4
rs72836561 17:41926126 CD300LG HDL 1.1×10−4 Phospholipids in large HDL 9.8×10−6 1.1
rs112777051 16:57470884 CIAPIN1-COQ9 HDL 1.7×10−4 Cholesterol esters in medium HDL 4.3×10−5 0.6
rs649129 9:136154304 ABO LDL 6.4×10−7 Conc. of very small VLDL particles 2.2×10−7 0.5
rs599839 1:109822166 SORT1 LDL 1.4×10−14 Ratio of apolipoprotein A-I to
apolipoprotein B
6.6×10−15 0.3
Variants at established lipid trait loci for which the METSIM association (P<5×10−5) for a subclass trait was stronger than for any of four conventional lipid
traits (HDL, LDL, TC, or TG). CM, chylomicrons. Chr, chromosome. IDL, intermediate-density lipoprotein.
§Log difference, −log10(Psubclass/Pconventional).
*Strongest associated conventional trait for the variant.
**Strongest associated subclass trait for the variant.
https://doi.org/10.1371/journal.pgen.1007079.t002
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The gene-based tests of association at LIPC and LIPG identified new rare coding variants
that may alter the function of these genes, and of lipid and lipoprotein subclass levels. While
the missense variants identified here all have mean normalized lipoprotein trait values above
the population mean, this type of analysis can help distinguish variants that lead to loss or
decrease vs gain or increase of gene function[53]. As well, the rise of whole exome sequencing
will likely uncover many more rare coding variants, including variants with unknown signifi-
cance on gene function. While it is still unclear which variants included in the gene-based tests
for LIPC and LIPG truly affect gene function, the comparison of trait values between carriers
of different variants may be used to help interpret the potential role of these variants in indi-
vidual carriers.
In conclusion, this GWAS of 72 lipid and lipoprotein subclass traits in 8,372 Finnish partic-
ipants in the METSIM study identified associations with 42 loci previously identified only with
the conventional lipid and lipoprotein traits[2], five novel signals associated with lipoprotein
subclasses, and eight rare, potentially functional, coding variants at LIPC and LIPG. Our use of
a dense reference panel of>15M variants combined with the high-throughput NMR-mea-
sured traits allowed us to conduct higher-resolution genetic analyses than reported previously.
Functional analysis of the variants identified in this study is the next step to determine which
variants and genes are affected, and replication of these lipid and lipoprotein subclass associa-
tions in women and in other ancestry groups will be useful to better understand the genetic
architecture of lipid and lipoprotein metabolism.
Materials and methods
Ethics statement
The METSIM study was performed in accordance with the Helsinki Declaration and was
approved by the Research Ethics Committee, Hospital District of Northern Savo (number 171/
2004). All study participants gave their written informed consent.
Study participants
Among the 10,197 participants in the METSIM study, we analyzed 8,372 non-diabetic individ-
uals (mean age 57±7 SD years and BMI 26.8±3.8 kg/m2)[55].
Subclass trait measurements
We measured the 72 lipid and lipoprotein traits from blood serum samples by proton NMR, as
previously described[56]. Briefly, lipid samples are extracted and measured by proton NMR,
and the NMR-spectra and automated phasing are compared to plate, background, and serum
controls. Regression modeling is used to quantify the spectral areas to produce the quantified
molecular data. The samples included 60 lipoprotein subclasses, 6 cholesterol and triglyceride
measures, 3 cholesterol diameter measures, and 3 apolipoprotein measurements (S1 Table).
Definition of the subclass traits has been previously described[56,57]. We visualized the Pear-
son correlation matrix between lipoprotein traits using a corrgram with the ellipse (https://
cran.r-project.org/web/packages/ellipse/) and lattice packages (http://lattice.r-forge.r-project.
org/) within R (S2 Fig)[58].
Genotyping and imputation
We genotyped the study samples using the HumanOmniExpress-12v1_C BeadChip and Infi-
nium HumanExome-12 v1.0 BeadChip, resulting in 631,879 and 236,849 variants, respectively.
Imputation was performed using the GoT2D reference panel of>19M variants (SNPs, in-dels,
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and large deletions) based on whole-genome sequence of 2,657 Europeans consisting of Ger-
man, Swedish, Finnish, and British participants; with the majority of the cohort comprised of
Finns[59]. The resulting 15,144,991 variants were subjected to quality controls including sam-
ple- and variant-level controls for detecting sample contamination, sex and relatedness confir-
mation, and detection of sample outliers using principal-component analysis. To exclude
samples with evidence of DNA contamination, we used BAFRegress v0.9 (http://genome.sph.
umich.edu/wiki/BAFRegress). Based on principal component analysis, eighteen exome array
sample duplicates, one individual each from seven monozygotic twin pairs, and twelve popula-
tion outliers were removed from analysis. Due to sex chromosome inconsistencies, fourteen
OmniExpress samples were removed. Samples with low genotype call rate (<95%) for either
array were removed. Variants with low-mapping quality to build hg19, low genotype com-
pleteness (<95% for OmniExpress and<98% for exome array), or multi-allelic variants were
removed. The remaining high quality variants were phased using Shape-It v2[60].
Single-variant analysis
We tested for association using imputed dosages for all variants with summed minor allele
count dosage >1 with each of the 72 lipid and lipoprotein traits assuming an additive model
and accounting for cryptic relatedness using the EMMAX linear mixed model approach as
implemented in EPACTS (http://genome.sph.umich.edu/wiki/epacts). Traits were adjusted for
age, age2, smoking status, and lipid lowering medication. Residuals were inverse normalized.
To assess the level of genomic inflation, we calculated the genomic control statistic (λGC) for
all of the trait-variant associations using R[58] (S1 Fig). Reported effect size regression coeffi-
cients (betas) sizes are given in standard deviation units. The rare lead associated variants that
were imputed and had MAF<0.01 were tested for genotype accuracy by using TaqMan assays
(Thermo Fisher Scientific) or Sanger sequencing in 499 METSIM participants who carried
one or more rare alleles at these variants. Variants that had>10% discordance between the
imputed genotype and the sequenced genotype in the examined individuals were removed
from the analysis. Variants with MAF<0.001 were excluded from analysis (S5 Table).
Compilation of existing lipid and lipoprotein trait associated variants
To identify variant association signals distinct or independent from those reported previously,
we identified variants previously reported to be associated with any cholesterol, lipid, lipopro-
tein, or triglyceride trait. We performed a literature review of GWAS and sequencing studies
using PubMed (https://www.ncbi.nlm.nih.gov/pubmed/) and Google Scholar (https://scholar.
google.com/), screened a GWAS Catalog (http://www.ebi.ac.uk/gwas/), and used SNIPPER
(https://csg.sph.umich.edu/boehnke/snipper/) to query publicly accessible databases. The
resulting curated list contained 1,714 variants, at>150 loci from 33 studies (S3 Table). The
resulting curated list contained 1,714 variants, at>150 loci from 33 studies (S3 Table). We
used this list to represent the known genome-wide lipid and lipoprotein-associated variants.
Conditional analyses
We LD-pruned (r2>0.95) the compiled list of 1,714 variants (S3 Table) to 885 variants (S4
Table) and we used this list (n = 885) in genome-wide conditional tests of association; this
stringent LD threshold facilitates conditioning on multiple known signals at a locus. Signals
that remained significant (Pconditional<5×10−8) after genome-wide conditional analysis were
considered novel and further tested by single-variant conditional analyses to determine inde-
pendence. At each of the five loci (Table 1), variants within 1 Mb up- and downstream of the
lead variant and on the compiled list of 1,714 variants were included in single-marker
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conditional analyses (S6 Table). Signals that remained significant (Psingle<5×10−8) after single-
variant conditional analysis were considered independent. Signals that only achieved a signifi-
cance threshold of Psingle<5×10−6 after single-variant conditional analysis were considered dis-
tinct. The single-variant conditional analyses considered variants within 1 Mb of the signal,
which accounts for<1% of the genome. Therefore, the significance thresholds for the distinct
and independent additional signals are conservative. At each locus, we validated that signals
were distinct/independent by reciprocal conditional analysis with the putative novel lead asso-
ciated variant for the trait. Additionally, the association data for the novel signals was adjusted
for each of the four conventional traits (HDL-C, LDL-C, TC, and TG), and the effect of the
association is reported in S7 Table.
Comparison of subclass trait associations with conventional lipid and
lipoprotein trait associations
For each of the 885 lipid/lipoprotein-associated variants (S4 Table), we determined whether
the variant showed stronger association with one of the 68 subclass traits compared to the four
conventional lipid traits (TC, TG, LDL-C, HDL-C). Variants were included for comparison if
the variant association with a subclass trait satisfied P<5×10−5 and if–log10pvalue for subclass
trait association was greater than any of the four conventional lipid traits.
Gene-based tests of association
To determine the contribution of rare coding variants, we used the Optimal Sequence Kernel
Association Test (SKAT-O) with EMMAX, as implemented in EPACTS, to test for gene-based
associations with the 72 lipoprotein traits[61]. Only coding variants directly genotyped on the
OmniExpress or Exome array were included, resulting in 709,600 variants. Since SKAT-O
requires no missing data, we imputed missing genotype data with the variant mean genotype.
We annotated coding variants using VEP. These annotations were the basis for four masks
that we implemented in the gene-based tests, as previously described[53]. Briefly, the four
masks were: Protein-Truncating Variants (PTV): no MAF limit; variants are nonsense, frame-
shift, or essential splice variants. PTV+missense: MAF<1%; all PTVs and missense variants.
PTV+Nonsynonymous strict (NSstrict): no MAF limit; all PTVs and missense variants pre-
dicted as deleterious by five variant annotation algorithms: LRT, Mutation Taster, PolyPhen2--
HumDiv, PolyPhen2-HumVar, and SIFT. PTV+NSstrict+NSbroad: MAF<1%; all variants in
PTV+NSstrict and variants predicted to be deleterious by any of the five algorithms above. Only
genes containing two or more variants in a given mask were tested. We conducted gene-based
conditional analyses to determine whether a single variant or a net-effect of multiple variants
could explain the observed association signal.
Variant annotation
To better characterize the novel signals from this study, we determined whether the associated
lead variants and LD proxies (r2>0.7 in METSIM) at each signal were within ChIP-seq peaks
of epigenomic transcriptional regulatory elements (S8 Table). We built lists of such elements
using data from the ENCODE Consortium[62] and Roadmap Epigenomics Project[63]. We
used datasets from three lipid and cholesterol relevant tissues (adipose, blood, and liver data-
sets) that were comprised of experimentally defined regions of transcription factor binding
sites (ChIP-seq), open chromatin (DNase- and FAIRE-seq), and histone modification marks
(H3K4me1, H3K4me2, and H3K4me3, H3K27ac, and H3K9ac).
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Supporting information
S1 Fig. Distribution of the METSIM lambda genomic control (GC) for the 72 lipoproteins.
(PDF)
S2 Fig. Correlogram showing Pearson correlations between lipoprotein traits. Correlogram
showing Pearson correlations between lipoprotein traits. Rows and columns are ordered
according to a complete linkage hierarchical clustering of traits based on the Pearson correla-
tion matrix. Percent correlation is shown for each trait-trait comparison. The color scale is
from red (negative correlation) to blue (positive correlation). The shapes are representations
of the correlation with a circle representing ‘no correlation’, ellipse representing ‘moderate
correlation’, and a diagonal line representing ‘high correlation’.
(PDF)
S3 Fig. Manhattan plots of traits. Manhattan plots for the five traits with signals identified
from this study. X-axis shows the chromosomes, and the y-axis is the–log10(Pvalue) for the
variant-trait association. The horizontal line is at the cutoff P = 5×10−8.
(PDF)
S4 Fig. Plots of the five association signals after conditioning on the 885 known lipid sig-
nals. Each circle represents a single variant. The color is based on LD (r2) between each variant
and the reference variant (purple diamond); X-axis, genomic (GRCh37/hg19) position in Mb;
Left y-axis, p- value of variant-trait association in–log10; Right y-axis, local estimates of geno-
mic recombination rate in cM/Mb, represented by blue vertical lines.
(PDF)
S5 Fig. Unconditional plots of the five lipid and lipoprotein subclass-associated loci. Each
circle represents a single variant. The color is based on LD (r2) between each variant and the
reference variant (purple diamond); X-axis, genomic (GRCh37/hg19) position in Mb; Left y-
axis, p-value of variant-trait association in–log10; Right y-axis, local estimates of genomic
recombination rate in cM/Mb, represented by blue vertical lines.
(PDF)
S6 Fig. Association of all 72 lipoprotein/lipid traits with the variants in Table 1. The Pvalue
is shown in -log10 and in the direction (+ or −) of the effect (Beta). The red line denotes the sig-
nificance cutoff of P5E-8. The red asterisk indicates the most significantly associated trait.
CAD, coronary artery disease.
(PDF)
S7 Fig. Association of all 72 lipoprotein/lipid traits with the variants in Table 2. The Pvalue
is shown in -log10 and in the direction (+ or −) of the effect (Beta). The red line denotes the sig-
nificance cutoff of P5E-8. The red asterisk indicates the most significantly associated trait.
CAD, coronary artery disease.
(PDF)
S1 Table. Characteristics of 8,372 METSIM study participants and 72 lipoprotein sub-
classes and triglyceride measures.
(XLSX)
S2 Table. 3,784 variants associated (P<5×10−8) with at least one of the 72 lipoprotein
traits. 3,784 unique variants that comprise the significant (P<5×10−8) 32,524 trait-variant
associations; Chr:position, hg19 chromosome and position; Genotype counts for homozygous
reference allele/heterozygous/homozygous alternate allele; MAC, minor allele count; MAF,
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minor allele frequency; P-value, best unconditional p-value for any of the 72 traits; Beta, effect
size of the alternate allele; Trait, trait with strongest association.
(XLSX)
S3 Table. Previously reported associations between 1,714 variants and one or more lipid or
lipoprotein traits. Variants and association data in this table were collected from 33 published
GWAS, fine-mapping, and exome-sequencing studies. The reported trait, Beta, and P-value
are taken from the study with the lowest p-value. N.R., data not reported in the study; Chr,
chromosome; Position, hg19; Trait, strongest associated trait from study shown; EA, effect
allele; NEA, non-effect allele; N, sample size of the study; Reference, the first study in the list is
the study with the lowest p-value for the given trait.
(XLSX)
S4 Table. 885 variants used for the conditional analysis (see Methods). Variants on this
table were trimmed from the 1,714 variants on S3 Table by using an r2>0.95 cutoff. The
reported trait, Beta, and P-value are taken from the study with the lowest p-value. N.R., data
not reported in the study; Chr, chromosome; Position, hg19; Trait, strongest associated trait
from study shown; EA, effect allele; NEA, non-effect allele; N, sample size of the study; Refer-
ence, the first study in the list is the study with the lowest p-value for the given trait.
(XLSX)
S5 Table. Variants that remained significantly associated (P<5×10−8) with at least one of
the 72 lipid or lipoprotein traits after conditioning on 885 known variants. Trait, subclass
trait (defined in S1 Table); Chr, chromosome; Genotype counts for homozygous reference
allele/heterozygous/homozygous alternate allele; MAC, minor allele count; MAF, minor allele
frequency; P-value, p-value for the variant after conditioning on 885 known lipid-associated
variants (S4 Table); Beta, effect size of the alternate allele; R2, variance explained.
(XLSX)
S6 Table. Results of single-marker and reciprocal conditional analyses for the associated
variants from this study. Lead variant, the most associated variant for the Lead Trait at a
given locus; Lead trait, the lipoprotein subclass or triglyceride measure with lowest p-value
across the 72 traits; Locus, biologically relevant gene within 1 Mb of lead variant; Chr, chromo-
some; MAF, minor allele frequency; Pdiscovery, unconditional p-value for the lead variant and
trait; Pconditional, p-value for the lead variant after conditioning on 885 known lipid GWAS vari-
ants (S4 Table); Conditional variant, known lipid or lipoprotein associated variants used for
single-marker conditional analyses; Psingle, p-value for the Lead variant after conditioning on
the Conditional variant; Ptrait, unconditional p-value of the Conditional variant for the Lead
trait; Preciprocal, p-value of the Conditional variant after conditioning on the Lead variant;
Conc, concentration; At chromosome 18, the variants identified in the gene-based test for
LIPG are in italics. § The effect of the unconditional p-value for the lead variant and trait after
adjusting for each of the four conventional traits.
(XLSX)
S7 Table. Results of conventional trait conditional analyses for the associated variants
from this study. Lead variant, the most associated variant for the Lead Trait at a given locus;
Lead trait, the lipoprotein subclass or triglyceride measure with lowest p-value across the 72
traits; Locus, biologically relevant gene within 1 Mb of lead variant; Chr, chromosome; MAF,
minor allele frequency; Pdiscovery, unconditional p-value for the lead variant and trait. § PHDL,
PLDL, PTC, and PTG, p-value for the lead variant and trait after adjusting for each of the four
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traits.
(XLSX)
S8 Table. Lipoprotein subclass and triglyceride measure loci associated variants that over-
lap epigenetic evidence of regulatory elements. Variants listed were in LD (r2>0.7) with the
lead trait variant (in bold) from this study and overlapped a regulatory element in relevant tis-
sue datasets. Abbreviations of the tissues tested for overlapping of regulatory elements are: A,
adipose; B, blood; L, liver. Chr, chromosome; Nearest coding TSS, distance from nearest GEN-
CODEv12 basic annotation transcription start site. Negative distance indicates the variant is
upstream of the TSS relative to the direction of transcription; N, total number of overlapping
datasets across experiments and cell types; Open chromatin, variants overlapping FAIRE/
DNase hypersensitivity elements; ChIP-seq Peak, Variant overlaps ChIP-seq peaks. Transcrip-
tion factor name:Tissue.
(XLSX)
S9 Table. Results of single-marker conditional analyses for the gene-based association data
from this study. Gene, gene tested in gene-based association tests; Lead trait, the lipoprotein
subclass or triglyceride measure with lowest p-value across the 72 traits; Pgene, p-value for the
gene and trait; Conditional variant, known lipid or lipoprotein associated variants used for sin-
gle-marker conditional analyses; Chr:Position, the hg19 chromosome and base-pair position
of the Conditional variant; P, p-value for the gene-based association after conditioning on the
Conditional variant.
(XLSX)
S10 Table. Comparison of METSIM association data between conventional lipid traits and
subclass traits at established coronary artery disease loci. Variants at established CAD loci
for which the METSIM association (P<5×10−5) for a subclass trait was stronger than for any
of four conventional lipid traits (HDL, LDL, TC, or TG). Log difference, log10(Psubclass/Pconven-
tional). Chr, chromosome.
(XLSX)
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